Entero Therapeutics, Inc. (NASDAQ:GRDX) Sees Significant Decline in Short Interest

Entero Therapeutics, Inc. (NASDAQ:GRDX) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 65,966 shares, a decrease of 44.6% from the August 15th total of 118,986 shares. Based on an average trading volume of 144,450 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.9% of the shares of the company are sold short.

Entero Therapeutics Stock Down 2.6%

GRDX traded down $0.08 during trading on Wednesday, reaching $2.94. 38,995 shares of the company’s stock were exchanged, compared to its average volume of 116,737. The company has a market capitalization of $20.96 million, a P/E ratio of -1.55 and a beta of 1.87. The business has a 50 day moving average price of $3.42 and a 200 day moving average price of $3.47. Entero Therapeutics has a fifty-two week low of $1.87 and a fifty-two week high of $6.93.

Analyst Ratings Changes

Separately, Wall Street Zen lowered shares of Entero Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 29th.

Entero Therapeutics Company Profile

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.